Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Drug Treatment, Treatment pathways, Clinical routine, Registry, Outcomes, Survival, Patient-related outcomes, Quality of life, Steroids, Azathioprine, N-Acetylcysteine, Pirfenidone, Tyrosine kinase inhibitors, Nintedanib, multicenter, Germany, Safety, Adverse event

Idiopathic pulmonary fibrosis (IPF), a manifestation of chronic progressive fibrosing interstitial pneumonia,ia a rare disease. Current treatment options are limited, and the mean survival time of the newly diagnosed (mostly elderly) patients is only about 2-3 years. As in Europe data are limited on the characteristics and management of such patients, INSIGHTS-IPF was initiated as a new registry that documents newly diagnosed (incident) and prevalent patients with confirmed IPF diagnosis prospectively.The registry will contribute to the optimization of the management of IPF patients in the long term.

INSIGHTS-IPF will report current and comprehensive data on Idiopathic Pulmonary Fibrosis (IPF) in the long-term. Baseline (cross-sectional part): Description of characteristics of IPF patients in terms of * key (socio-) demographic data * IPF risk factors, comorbidities * methods used for IPF diagnosis * IPF disease severity and manifestation (including lung function, cardiopulmonary exercise testing and/or exercise capacity if available, laboratory values, biomarkers) * IPF treatment (detailed information on prescribed drugs and doses; non-pharmacological treatment; listing and score for lung transplantation) * assessment of patient-related outcomes (PRO) such as quality of life Follow-up (prospectively up to at least 2 years after inclusion): * Clinical course of IPF (e.g. in terms of symptoms, lung function, exercise capacity if available) * Documentation of treatment pathways (switch/add-on/discontinuation of medication), and of non-pharmacological treatment (e.g. start of long term oxygen therapy; new listing for lung transplantation)Outcomes/events (such as acute respiratory worsening, exacerbations, hospitalisation due to any cause and due to IPF, other complications, survival) * Patient-related outcomes such as quality of life, assessed once a year(for comparison with baseline) * Resource use for pharmacoeconomic analyses.

None listed

Germany